BioStock: Chordate introduces migraine treatment in Finland

Chordate Medical recently presented positive results from the German part of a large migraine study showing that K.O.S is an effective and safe treatment for chronic migraine. With these study results, the company chooses to broaden its focus on chronic migraine and introduce the treatment in Finland, as the successful PM007 study also includes Finnish clinics. The company’s CEO Anders Weilandt tells us more in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/chordate-introduces-migraine-treatment-in-finland/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se